ezlopitant

**Ezlopitant** is a selective, non-peptidic small molecule neurokinin-1 receptor (NK1R) antagonist developed by Pfizer for the treatment of chemotherapy-induced nausea and vomiting (CINV), irritable bowel syndrome (IBS), and pain[1][3][5][7][9][12][13]. Its mechanism involves antagonism of the substance-P (NK1) receptor, thereby inhibiting substance P-mediated signaling implicated in emesis, gastrointestinal motility, and pain[1][3][5][12][13].

Other names

ezlopitant (USAN/INN)(2S,3S)-2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine(2s,3s)-2-(diphenylmethyl)-n-(5-isopropyl-2-methoxybenzyl)quinuclidin-3-amine2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amineCJ-11,974147116-64-1ezlopitantum